A Phase II, Open Label, Single Arm Study of Ipilimumab and Nivolumab With Salvage Radiotherapy in Patients With Melanoma Brain Metastases

Trial Profile

A Phase II, Open Label, Single Arm Study of Ipilimumab and Nivolumab With Salvage Radiotherapy in Patients With Melanoma Brain Metastases

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Nov 2017

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Brain metastases; Malignant melanoma
  • Focus Therapeutic Use
  • Acronyms The ABC-X Study
  • Most Recent Events

    • 16 Nov 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top